Rapid stereology based quantitative immunohistochemistry of dendritic cells in lymph nodes: A methodological study

Citation
Y. Van Hensbergen et al., Rapid stereology based quantitative immunohistochemistry of dendritic cells in lymph nodes: A methodological study, ANAL CELL P, 22(3), 2001, pp. 143-149
Citations number
18
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Journal title
ANALYTICAL CELLULAR PATHOLOGY
ISSN journal
09218912 → ACNP
Volume
22
Issue
3
Year of publication
2001
Pages
143 - 149
Database
ISI
SICI code
0921-8912(2001)22:3<143:RSBQIO>2.0.ZU;2-6
Abstract
This study was done to arrive at a fast and reliable protocol for assessmen t of fractional volumes of immunohistochemically stained dendritic cells in lymph nodes. Twenty axillary lymph nodes of patients with locally advanced breast cancer were immuno-histochemically stained with an S100 antibody. F ractional volumes of dendritic cells were assessed by stereology based quan titative immunohistochemistry using an interactive video overlay system inc luding an automated microscope. The gold standard percentage of dendritic c ells was the fractional volume of S100 stained cells in 500 fields systemat ically spread over the whole lymph node. Then, in a computer simulation, di fferent sample sizes (1-200 fields of vision) were tested and the coefficie nt of variation (CV) for each sample size was calculated. The CV dropped wi th increasing sample size. A sample size of 100 fields of vision appeared t o be optimal. Intra- and interobserver reproducibility appeared to be good (correlation coefficients of 0.95 and 0.86, respectively) when re-analyzing the cases with the established protocol. In conclusion, a fast and reliable assessment of the fractional volume of d endritic cells in lymph nodes is possible with semi-automated quantitative immuno-histochemistry. This method will form the base for further clinical studies into the immunological response in lymph nodes of patients with loc ally advanced breast cancer.